Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 19/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484049 | 0.90 | PDE2A (0.43) | PDE2AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4493516 | 0.79 | PDE2A (0.37) | PDE2A | |
| SCHEMBL4480515 | 0.76 | PDE2A (0.39) | PDE2A | |
| SCHEMBL6992630 | 0.76 | PDE2A (0.42) | PDE2AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4820826 | 0.76 | PDE2A (0.40) | PDE2A | |
| SCHEMBL4489320 | 0.76 | PDE2A (0.34) | PDE2A | |
| SCHEMBL4813005 | 0.75 | PDE2A (0.44) | PDE2AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4815253 | 0.75 | PDE2A (0.39) | PDE2A | |
| SCHEMBL4811909 | 0.74 | PDE2A (0.43) | PDE2AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13920303 | 0.74 | PDE2A (0.43) | PDE2AKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507739-B2 | 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1680425-B1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1680425-A1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005030775-A1 | 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | ABCC1, ABCB1, TUBB6 | PDE2A 3428/4885KDM4E 2907/4885ALDH1A1 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.